In a regulatory filing last night, Rocket Pharmaceuticals (RCKT) disclosed that its director Elisabeth Bjork bought 10K shares of common stock on August 27th in a total transaction size of $34.1K. Shares are up 2.4% in pre-market at $3.40.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Promising Outlook for Rocket Pharmaceuticals: Buy Rating Affirmed Amidst Advancements in RP-A501 Study
- Rocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunities
- EMA says Rocket Pharmaceuticals withdraws MA application for Fanskya
- Hold Rating on Rocket Pharmaceuticals Amid Uncertainties in RP-A501 Study Resumption
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!